Life-Changing Therapy Is Here

Life-Changing Therapy Is Here

We all welcomed the news when the U.S. Food and Drug Administration (FDA) approved Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.  And, now our implementation team is making sure every process is in place to welcome Gattex patients.  The drug will be available within the next few weeks, and our team recognizes the importance of this – and every – therapy supported by our Specialty Pharmacy services. 

Gattex is the first and only long-term targeted therapy that addresses the underlying issue of short bowel syndrome, which is mal-absorption.  Short bowel syndrome patients can be hooked to an intravenous line 10 to 12 hours each day.  The Gattex studies showed that more than half of the patients gained at least one infusion-free day each week, and nearly a quarter of patients achieved three or more infusion-free days each week.  This could translate into anywhere from 50 to 150 days of independence from parenteral support each year.  Simple activities many of us take for granted, like traveling from home for a weekend or getting a night of uninterrupted sleep, can now be experienced by Gattex patients. 

Our clinical care team is ready to educate and support Gattex patients as they begin this life-changing therapy.  Our nurses will teach patients how to inject the drug and make follow up calls to evaluate patients’ dosage and progress on the therapy. 

It’s important to note, once again, that small patient populations rely on manufacturers for big solutions as they work to manage these life-changing therapies.  Through our specialty pharmacies and UBC patient access services, it’s our job to make sure those big solutions for orphan and ultra-orphan products are integrated and implemented in a way that exceeds patient and prescriber expectations.